Open AccessEffect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
Author(s) -
M.P. Oapos;Brien,
E. Forleo-Neto,
N. Sarkar,
F. Isa,
P. Hou,
Kuo- Chen Chan,
B.J. Musser,
K.J. Bar,
R.V. Barnabas,
D.H. Barouch,
M.S. Cohen,
C.B. Hurt,
D.R. Burwen,
M.A. Marovich,
E.R. Brown,
I. Heirman,
J.D. Davis,
Kyrin Turner,
D. Ramesh,
A. Mahmood,
A.T. Hooper,
J.D. Hamilton,
Y. Kim,
L.A. Purcell,
A. Baum,
C.A. Kyratsous,
J. Krainson,
R. Perez-Perez,
Rahimeh Mohseni,
B. Kowal,
A.T. Dicioccio,
G.P. Geba,
N. Stahl,
L. Lipsich,
N. Braunstein,
G. Herman,
G.D. Yancopoulos,
D.M. Weinreich
Publication year - 2022
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/ekjy-d912
Subject(s) - asymptomatic , covid-19 , medicine , randomized controlled trial , placebo , clinical trial , antibody , virology , immunology , pathology , outbreak , disease , alternative medicine , infectious disease (medical specialty)